The efficacy of Keverprazan based quadruple therapy for Helicobacter pylori eradication:a phase III, randomized, double-blind, multicenter trial

Keverprazan is a novel potassium-competitive acid blocker. The advantages of keverprazan as a potent acid suppressor in Helicobacter pylori eradication have not yet been demonstrated. The aim of this study was to evaluate the efficacy of keverprazan as a component of bismuth quadruple therapy in H. pylori treatment.